Intellia Therapeutics (NTLA) Total Non-Current Liabilities (2015 - 2025)

Intellia Therapeutics (NTLA) has 9 years of Total Non-Current Liabilities data on file, last reported at $170.7 million in Q4 2025.

• On a quarterly basis, Total Non-Current Liabilities fell 46.49% year-over-year to $170.7 million in Q4 2025; TTM through Dec 2025 was $170.7 million, a 46.49% decrease from a year earlier, with the FY2025 full-year figure at $170.7 million, down 46.49% from the prior year.
• Total Non-Current Liabilities for Q4 2025 stood at $170.7 million, down from $319.1 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for NTLA reached as high as $1.4 billion in Q1 2023 and fell as low as $170.7 million in Q4 2025.
• Historically, Total Non-Current Liabilities has averaged $781.8 million across 5 years, with a median of $1.1 billion in 2022.
• Across the five-year window, Total Non-Current Liabilities tumbled 80.68% in 2023 and increased 27.21% in 2024, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $1.3 billion in 2021, then sank by 79.88% to $260.5 million in 2022, then decreased by 3.72% to $250.8 million in 2023, then rose by 27.21% to $319.1 million in 2024, then plunged by 46.49% to $170.7 million in 2025.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $170.7 million in Q4 2025, $319.1 million in Q4 2024, and $250.8 million in Q4 2023.